News & Events
News & Events
February 17, 2023
C-Path Stands with Bruce Willis, Neurodegenerative Disease Community After FTD DiagnosisC-Path and its members stand with Bruce Willis and his family as they bravely revealed the difficult news of his Frontotemporal Degeneration (FTD) diagnosis yesterday. Also known as frontotemporal degeneration, the Association for Frontotemporal Degeneration (AFTD) defines FTD as a group of brain disorders caused by degeneration of the frontal and/or temporal lobes of the...
January 25, 2023
C-Path Receives Letter of Support from EMA on Duchenne Muscular Dystrophy Clinical Trial Simulation Platform
C-Path today announced that the European Medicines Agency (EMA) has issued a letter of support for the Duchenne Regulatory Science Consortium’s (D-RSC) Model-based Clinical Trial Simulation Platform for Duchenne Muscular Dystrophy (DMD).
September 27, 2022
Global Biopharmaceutical Leader to Usher C-Path in Next Phase of Growth and Innovation
C-Path today named Daniel M. Jorgensen, M.D., MPH, MBA, its Chief Executive Officer (CEO). An experienced leader in drug development, healthcare and business, Jorgensen will continue C-Path’s distinguished reputation of collaboration with global stakeholders, including patient groups, academic institutions, the pharmaceutical industry and regulatory agencies, to set a vision for C-Path’s next phase of growth and innovation. Jorgensen’s tenure as CEO will commence on the first of October.
September 14, 2022
C-Path Awarded FDA Grant to Establish Public-Private Partnership to Advance Treatments for Rare Neurodegenerative Diseases
C-Path has announced it will serve as the convener of the Critical Path for Rare Neurodegenerative Diseases (CP-RND), a new public-private partnership (PPP) to benefit people across multiple rare neurodegenerative diseases, supported by a grant from the U.S. Food and Drug Administration (FDA). The Agency announced the PPP today in a press release.
September 8, 2022
C-Path’s Kristen Swingle Named PresidentSwingle joined C-Path in 2019 and was named interim president in 2021 TUCSON, Ariz., Sept. 8, 2022 — Critical Path Institute (C-Path) today announced that its Chief Operating Officer (COO) and Interim President, Kristen Swingle, M.S., has been named COO and President, effective immediately. Swingle has filled the interim President role since 2021, stewarding C-Path...